Amneal Pharmaceuticals (AMRX) EPS (Weighted Average and Diluted) (2018 - 2026)

Amneal Pharmaceuticals' EPS (Weighted Average and Diluted) history runs 9 years deep, the most recent figure standing at $0.19 for Q1 2026.

• In Q1 2026, EPS (Weighted Average and Diluted) rose 375.0% year-over-year to $0.19; the TTM figure through Mar 2026 stood at $0.38 (up 1050.0% YoY), while the FY2025 annual figure was $0.22, up 157.89% from the prior year.
• EPS (Weighted Average and Diluted) was $0.19 for Q1 2026 at Amneal Pharmaceuticals, up from $0.11 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.19 in Q1 2026 to a low of -$0.8 in Q2 2022.
• Historically, EPS (Weighted Average and Diluted) has averaged -$0.07 across 5 years, with a median of $0.01 in 2025.
• Biggest YoY gain for EPS (Weighted Average and Diluted) was 400.0% in 2023; the steepest drop was 1800.0% in 2023.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.03 in 2022, then sank by 1800.0% to -$0.57 in 2023, then jumped by 82.46% to -$0.1 in 2024, then jumped by 210.0% to $0.11 in 2025, then jumped by 72.73% to $0.19 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.19 (Q1 2026), $0.11 (Q4 2025), and $0.01 (Q3 2025), per Business Quant data.